Table 4 Univariate analysis of possible risk factors for survival.
Characteristics | Relapse-free survival | Overall survivals | ||
|---|---|---|---|---|
Rates | p values | Rates | p value | |
Ages (years) | ||||
>50 | 41.7% | 0.97 | 58.8% | 0.36 |
≤50 | 31.9% | 62.8% | ||
Gender | ||||
Male | 40.4% | 0.21 | 60.2% | 0.43 |
Female | 22.5% | 62.4% | ||
Histological types | ||||
Nonkeratinizing carcinoma, undifferentiated | 29.5% | 0.26 | 75% | 0.48 |
Nonkeratinizing carcinoma, differentiated | 59.7% | 66.9% | ||
Keratinizing squamous cell carcinoma | 75% | 57.9% | ||
Recurrent NPC Galectin-9 expression | ||||
Low | 45.4% | 0.004 | 69.4% | 0.06 |
High | 29.7% | 53.2% | ||
TILs CD8+ lymphocytes | ||||
Low | 26.1% | 0.005 | 53.5% | 0.06 |
High | 46.6% | 69.1% | ||
TILs CD4+ lymphocytes | ||||
Low | 44.6% | 0.21 | 65.1% | 0.20 |
56.5% | ||||
High | 29.5% | |||
TILs Foxp3+ lymphocytes | ||||
Low | 50.2% | 0.004 | 68.9% | 0.08 |
53.8% | ||||
High | 25.8% | |||
TILs Tim-3+ lymphocytes | ||||
Low | 42.2% | 0.32 | 61.8% | 0.65 |
High | 31.0% | 59.7% | ||
Initial stage | ||||
Early stages (I/II/III) | 35% | 0.33 | 58.4% | 0.36 |
63.1% | ||||
Advanced stages (IVA/IVB) | 39.1% | |||
Recurrent stage | ||||
Early stages (rI/rII/rIII) | 58.4% | <0.001 | 79.8% | <0.001 |
Advanced stages (rIVA/rIVB/rIVC) | 10.9% | 36.9% | ||
